ProPharma’s team of dedicated experts is at the forefront of both existing and emerging industry trends. ProPharma’s team inspires tomorrow by leveraging rich data insights across our service lines and functional areas to develop innovative solutions that answer the most complex needs of both existing and prospective clients.
Digital Transformation in Life Sciences: The Importance of Data Strategy
What is Digital Transformation?
While there are many different definitions of digital transformation in life sciences, the core concepts they all have in common are digital technology and creating new, or modifying existing, ways of working. The underlying business driver is that digital...
FDA Updates Guidelines for Biosimilar Naming Convention
On August 28, 2015, FDA announced the availability of a draft guidance, entitled “Nonproprietary Naming of Biological Products,” which established a naming convention for biological products. The...
FDA Issues Draft Guidance on Adhesion Studies for Generic Topical Patches
On Wednesday, June 1st the FDA issued a draft guidance that provides various recommendations concerning studies to evaluate the adhesion performance of a Transdermal Delivery System (TDS) or a...
On May 10th the Food and Drug Administration (FDA) published a final rule expanding regulation to a range of products that meet the statutory definition of a “tobacco product,” including...
FDA Approves Implant Device to Treat Opioid Addiction
On Thursday, May 26th, FDA announced the approval of Probuphine® , a buprenorphine implant for the treatment of opioid dependence. The implant is the first device of its kind, and “is designed to...
Earlier this week Samsung Bioepis announced that FDA has accepted for review its BLA for SB2, a biosimilar version of Remicade (infliximab). SB2 is indicated for the treatment of rheumatoid...
FDA Warns of Possible Amputation Risk Associated with Diabetes Drug
On Wednesday, May 18th, FDA issued a Drug Safety Communication alerting the public of potential risks associated with canagliflozin (Invokana, Invokamet), which is used for the treatment of type 2...
FDA Finalizes Guidance Containing Postmarket Surveillance Recommendations, Part Two: Postmarket Surveillance Plans & Reports
Additional information on FDA’s final guidance is available in our preceding FDA News article, entitled “FDA Finalizes Guidance Containing Postmarket Surveillance Recommendations, Part One:...
FDA Finalizes Guidance Containing Postmarket Surveillance Recommendations, Part One: Background & Pre-522 Postmarket Surveillance Process
On Monday, May 16th, the FDA issued a final guidance, entitled “Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act.” A draft of the guidance was published on August...
Clinical Trials Day 2016: Increasing Clinical Trial Awareness & Participation
Every year on or near May 20th, Clinical Trials Day is celebrated. The internationally observed celebration recognizes the first randomized clinical trial, conducted in 1747 by James Link. In a...
Understanding Statistical Intervals: Part 2 - Prediction Intervals
Part 1 of this series discussed confidence intervals. Confidence intervals are the best known of the statistical intervals but they only bound regions associated with population parameters; i.e., the...
In order to incentivize the development of therapies (drugs biologics) to fill unmet medical needs for treatment of serious conditions, the FDA has developed various programs to expedite drug...
What is a Clinical Study Report? A Clinical Study Report (CSR) is a document that describes the methods and results of a clinical study or trial, along with a short discussion of key findings related...
Patient Support Programs (PSPs) in the pharmaceutical sector represent an array of aimed at supporting patients in initiating therapy and maintaining adherence. PSPs, also known as Patient Assistance...
The link between statistical methods and healthcare is not a new one, but the volume of available data to inform healthcare decisions and the use of data science in the medical industry has exploded...
Formal FDA Meetings for Sponsors or Applications of PDUFA Products
This article has been updated since its original February 28, 2017 publication. Since the introduction of the Prescription Drug User Fee Act (PDUFA) VII for fiscal years 2023 - 2027, the FDA...